FOSUN PHARMA's (600196.SH) Subsidiary Receives FDA Approval for Drug

Stock News11-14

FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiary have obtained U.S. FDA approval for the Biologics License Application (BLA) of their self-developed POHERDY®1 (420mg/14mL (30mg/mL)) injection (for intravenous use) (pertuzumab, project code: HLX11). The approved indications include: (1) Combination therapy with trastuzumab and docetaxel for the treatment of HER2-positive, metastatic breast cancer (MBC) in adult patients who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease; (2) Combination therapy with trastuzumab and chemotherapy as: ① part of a comprehensive treatment plan for early breast cancer in HER2-positive, locally advanced, inflammatory, or early-stage breast cancer patients (tumor diameter >2cm or lymph node-positive) for neoadjuvant treatment; and ② adjuvant treatment for adult patients with HER2-positive early breast cancer at high risk of recurrence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment